Pharmacogenetic Study of Obsessive-Compulsive Disorder
Information source: Severance Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Obsessive-Compulsive Disorder
Intervention: SSRIs (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Severance Hospital Official(s) and/or principal investigator(s): Se Joo Kim, M.D., Principal Investigator, Affiliation: Professor, Department of Psychiactry, Yonsei Univ. College of Medicine
Overall contact: Se Joo Kim, M.D., Phone: +82-2-2228-1627, Email: kimsejoo@yuhs.ac
Summary
The purpose of this study is to determine whether pharmacogenetic study predict selective
serotonin reuptake inhibitor (SSRI) responsiveness in advance before the appearance of the
drug effect until 4 months(16 weeks), 6 months, and 1 year after administration of SSRIs.
Clinical Details
Official title: Pharmacogenetic Study of Obsessive-Compulsive Disorder
Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
Primary outcome: Change from baseline in the Yale-Brown Obsessive-Compulsive Scale
Secondary outcome: Change from the baseline Montgomery-Asberg Depression Rating ScaleOccurrence of any side effects during the SSRIs treatment
Detailed description:
The purpose of this study is to determine the effects of genetic variants on the response to
SSRIs in obsessive-compulsive disorder (OCD) subject.
The investigators will recruit drug-naive or drug-free(> 3 months) OCD subjects (n=200). The
participants will get SSRIs for their OCD symptoms. The type and dose of SSRIs will not be
restricted and will depend on the individual participant's state. However, the
investigators will be recommended to follow usual clinical guideline (the Korean treatment
algorithm for OCD, 2004). At baseline, 4 month, 6 months, and 1 year after treatment, the
participants will be evaluated by Yale-Brown Obsessive-Compulsive Scale(YBOCS), Montgomery
Asberg Depression Rating Scale(MADRS), Dimensional Obsessive-Compulsive Scale(DOCS), Toronto
alexithymia scale (TAS), interpersonal reactivity index (IRI), Barratt impulsiveness scale
(BIS), and the Measure of Constructs Underlying Perfectionism(M-CUP).
And all the participants will donate 5 ml of whole blood and DNA will be extracted.
Using various genetic analyses methods such as genotyping, exome sequencing, and so on we
will analyze the association of various genetic variants and the anti-obsessive-compulsive
responses.
Eligibility
Minimum age: 19 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. age 19~ 60
2. OCD by Diagnostic and Statistical Manual for Mental disorders, 4th edition (DSM-IV)
3. drug naive or drug free for more than 3 months
Exclusion Criteria:
1. any neurological disorder
2. comorbid psychotic disorders
3. alcohol or other substance dependence within past 6 months
4. any evidences for brain diseases
Locations and Contacts
Se Joo Kim, M.D., Phone: +82-2-2228-1627, Email: kimsejoo@yuhs.ac
Yonsei Univ. Health System Severance Hospital, Seoul 120-752, Korea, Republic of; Recruiting Se Joo Kim, M.D., Phone: +82-2-2228-1620, Email: kimsejoo@yuhs.ac Jee In Kang, M.D., Phone: +82-2-2228-1620, Email: kji0354@yahoo.co.kr Se Joo Kim, M.D., Principal Investigator Jee In Kang, M.D., Sub-Investigator
Additional Information
Starting date: January 2013
Last updated: April 27, 2015
|